Genmab A (GMAB) Stock: Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Sep 30, 2026: 0 added, 1 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about GMAB filings

Are insiders buying or selling Genmab AS (GMAB) stock?

Neither. Genmab AS (GMAB) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded GMAB recently?

None. No member of Congress disclosed a GMAB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GMAB smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on GMAB

Lean long1 source:
- Funds

Top traders
No tracked positions at the last update
Insiders
No recent insider filings found
Congress
No recent politician filings found
Funds
Lean long2 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about GMAB filings

Are insiders buying or selling Genmab AS (GMAB) stock?

Neither. Genmab AS (GMAB) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded GMAB recently?

None. No member of Congress disclosed a GMAB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GMAB smart-money data?

Funds

What funds are doing

4 moves · 6 mo

Buys/Adds$109.9MSells/Trims$31.2M

Buys/Adds (2)

CI
Citadel
Ken Griffin · Q2 2026 13F
$68.0M
bought
Signals like this: n=3228, 54% finished lower at D15, median -0.8% vs SPY -0.4%
QR
Qube Research
Q2 2026 13F
$28.2M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Sells/Trims (1)

QR
Qube Research
Q3 2026 13F
$31.2M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

1 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 1 moves

Other smart money signals

Activist stakes, short interest & more

2 items

F1
Filing 13d GLight
Darwin Global Management, Ltd. filed SC 13G on GENMAB A/S (passive 5.90% stake)
SI
Short Interest ChangeModerate
short-volume tape softening: latest 55.6% fell 11.9pp vs 20d avg 67.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 5, 2026

Earnings came in 55.6% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 5, 2026

Period ending

Sep 30, 2026

Earnings per share

$0.56+55.56% beat

$0.36 expected

Revenue

$1.19B

Financial statements: Alpha Vantage

Next report

What the street expects next

Estimates as of Nov 11, 2026

EPS expected

$0.16

$0.07 to $0.24

Revenue expected

$8.44B

9 analysts

Last 30 days

1up3down

Analysts cutting estimates

Estimate drift

0.11

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 5, 2026	$0.56est. $0.36	+55.56%beat	$1.19BAlpha Vantage	No year-ago quarter
Jun 30, 2026Reported Aug 6, 2026	$0.54est. $0.37	+45.95%beat	$1.16BSEC filing	+24.9%from $925.0M
Mar 31, 2026Reported May 7, 2026	$0.13est. $0.19	-29.74%miss	DKK 899.3MAlpha Vantage	+754.6%from DKK 105.2M
Dec 31, 2025Reported Feb 17, 2026	$0.21est. $0.37	-44.55%miss	DKK 1.05BAlpha Vantage	-83.6%from DKK 6.44B
Sep 30, 2025Reported Nov 6, 2025	$0.65est. $0.45	+44.44%beat	DKK 1.02BAlpha Vantage	-81.6%from DKK 5.54B
Jun 30, 2025Reported Aug 7, 2025	$0.54est. $0.39	+38.46%beat	$925.0MSEC filing	No year-ago quarter
Mar 31, 2025Reported May 8, 2025	$0.31est. $0.23	+34.78%beat	DKK 105.2MAlpha Vantage	-82.5%from DKK 603.0M
Dec 31, 2024Reported Feb 12, 2025	$0.84est. $0.28	+$0.56beat	DKK 6.44BAlpha Vantage	+37.7%from DKK 4.68B

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $52.20
High: $53.03
Low: $51.54
Prev close: $53.87
52-wk high: $59.97
52-wk low: $23.62
Mkt cap: $31.90B
P/E: 44.2x
ROE: +12.1%
Fwd P/E: 23.0x
Beta: 0.52
P/S: 7.4x
P/B: 5.2x
Profit margin: +17.0%
Op margin: +30.6%

Sep 2026 to Sep 2026

What it sold, what it cost, what was left.

RevenueProfit

Sep 2026

Income statement, 1 periods, all values in US dollars
USD	Sep 2026
What came in
RevenueTotal revenue	$1.19B
Cost of what it soldCost of revenue	$88.0M
Gross profit	$1.10B
What it spent
Research and development	$451.0M
Sales and adminSelling, general and administrative	$196.0M
Other operating costsOperating costs not itemised in the filing's summary	$11.0M
Total operating expenses	$658.0M
What was left
Operating profitOperating income	$441.0M
Interest on debtInterest expense	$111.0M
Profit before tax	$354.0M
TaxIncome tax expense	$12.0M
Net profitNet income	$342.0M
EBITDAEarnings before interest, tax, depreciation, amortisation	$492.0M

Technicals

Price structure

This stock is in a strong uptrend.

Trend

Strong uptrend

100 / 100

RSI 14

64balanced

20D volatility

101%annualized

52-week range

$51.74

$23.62$59.97

20D support

$36.74recent floor

20D resistance

$59.97recent ceiling

Returns

5D -1.9%20D +36.8%60D +51.7%

Price vs moving averages

SMA20 +5.0%SMA50 +26.8%SMA200 +64.5%

Volume pace

1.58xvs prior 20D

News

What the news says

16 articles · 7 days

Coverage is bullish

12 bullish · 3 neutral · 1 bearish

Transactions with shares and linked securities in Genmab
NeutralNov 10
Genmab shares rise 4% on J&J cancer drug FDA approval
NeutralNov 9
Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half
BullishNov 9
Genmab A/S (GMAB) Seasonal returns chart
NeutralNov 7
Genmab’s Phase 3 LiGeR-HN1 Trial Met Primary Endpoints of Overall Survival and Response Rate in HNSCC
BullishNov 6
Genmab AS ADR earnings beat by $0.20, revenue fell short of estimates
Leans bullishNov 6
What Genmab A/S (GMAB) Said on Its Q3 Earnings Call
BullishNov 5
Genmab Q3 2026 Earnings Call Transcript
BullishNov 5

31 macro signals shaping GMAB right now

Unlock sector rotation, regime shifts, and macro event windows tied to this stock.

Unlock the full results

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 5, 2026

$0.56est. $0.36

+55.56%

$1.19BAlpha Vantage

No year-ago quarter

Jun 30, 2026Aug 6, 2026

$0.54est. $0.37

+45.95%

$1.16BSEC filing

+24.9%from $925.0M

Mar 31, 2026May 7, 2026

$0.13est. $0.19

-29.74%

DKK 899.3MAlpha Vantage

+754.6%from DKK 105.2M

Dec 31, 2025Feb 17, 2026

$0.21est. $0.37

-44.55%

DKK 1.05BAlpha Vantage

-83.6%from DKK 6.44B

Sep 30, 2025Nov 6, 2025

$0.65est. $0.45

+44.44%

DKK 1.02BAlpha Vantage

-81.6%from DKK 5.54B

Jun 30, 2025Aug 7, 2025

$0.54est. $0.39

+38.46%

$925.0MSEC filing

No year-ago quarter

Mar 31, 2025May 8, 2025

$0.31est. $0.23

+34.78%

DKK 105.2MAlpha Vantage

-82.5%from DKK 603.0M

Dec 31, 2024Feb 12, 2025

$0.84est. $0.28

+$0.56

DKK 6.44BAlpha Vantage

+37.7%from DKK 4.68B

Income statement, 1 periods, all values in US dollars
USD	Sep 2026
What came in
RevenueTotal revenue	$1.19B
Cost of what it soldCost of revenue	$88.0M
Gross profit	$1.10B
What it spent
Research and development	$451.0M
Sales and adminSelling, general and administrative	$196.0M
Other operating costsOperating costs not itemised in the filing's summary	$11.0M
Total operating expenses	$658.0M
What was left
Operating profitOperating income	$441.0M
Interest on debtInterest expense	$111.0M
Profit before tax	$354.0M
TaxIncome tax expense	$12.0M
Net profitNet income	$342.0M
EBITDAEarnings before interest, tax, depreciation, amortisation	$492.0M

USD

Sep 2026

What came in

RevenueTotal revenue

$1.19B

Cost of what it soldCost of revenue

$88.0M

Gross profit

$1.10B

What it spent

Research and development

$451.0M

Sales and adminSelling, general and administrative

$196.0M

Other operating costsOperating costs not itemised in the filing's summary

$11.0M

Total operating expenses

$658.0M

What was left

Operating profitOperating income

$441.0M

Interest on debtInterest expense

$111.0M

Profit before tax

$354.0M

TaxIncome tax expense

$12.0M

Net profitNet income

$342.0M

EBITDAEarnings before interest, tax, depreciation, amortisation

$492.0M

Genmab AS

Smart money at a glance

What do analysts expect?

Questions about GMAB filings

Smart money on GMAB

Questions about GMAB filings

What funds are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 55.6% above what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

What the news says

Ask it in Claude or ChatGPT.

Genmab AS

Smart money at a glance

What do analysts expect?

Questions about GMAB filings

Smart money on GMAB

Questions about GMAB filings

What funds are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 55.6% above what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

What the news says

Ask it in Claude or ChatGPT.

Genmab AS

Overview

Questions about GMAB filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

News

Macro

Ask it in Claude or ChatGPT.

Genmab AS

Overview

Questions about GMAB filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

News

Macro

Ask it in Claude or ChatGPT.